Article
Significance of targeted therapy and genetic alterations in EGFR, ALK, or KRAS on survival in patients with non-small cell lung cancer treated with radiotherapy for brain metastases.
Neuro-oncology - 1 Feb 2015
Mak Kimberley S, Gainor Justin F, Niemierko Andrzej, Oh Kevin S, Willers Henning, Choi Noah C, Loeffler Jay S, Sequist Lecia V, Shaw Alice T, Shih Helen A
Abstract excerpt
BACKGROUND: We determined the impact of genetic alterations in EGFR, ALK, or KRAS on survival after radiotherapy for brain metastases in non-small cell lung cancer (NSCLC). METHODS: Of 172 genotyped NSCLC patients treated with radiotherapy for brain metastases in 2005-2012, 54 had cancers with EGFR mutations, 12 had ALK rearrangements, 38 had KRAS mutations, and 68 were wild-type (WT). Overall survival (OS) was...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.